3 results
Primary Objective: The primary objective is to evaluate the efficacy of daratumumab plus CyBorD compared with CyBorDalone in the treatment of newly diagnosed AL amyloidosis patients.Secondary Objectives:# To evaluate the clinically observable…
The purpose of this study is to determine the sustained benefit on safety and efficacy of AMG 334 compared to oral prophylactics in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments and therefore have a…
Primary objective: To determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared to active monitoring in subjects with high-risk smoldering multiple myeloma (SMM).Secondary…